Payments to doctors linked to prescription practices for two cancer types
(UNC Lineberger Comprehensive Cancer Center) Compared to physicians who didn't receive any payments, those who received general payments for meals and lodging from a drug manufacturer had higher odds of prescribing that company's particular drug for metastatic renal cell carcinoma and for chronic myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2018 Category: Cancer & Oncology Source Type: news
Treatment - Free Remission Feasible After Nilotinib in CML
For patients with chronic myeloid leukemia in chronic phase, TFR is feasible after second - line treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 26, 2018 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news
FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). (Source: World Pharma News)
Source: World Pharma News - December 22, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
FDA Approves Pfizer ’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
December 19, 2017 -- Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for Bosulif (bosutinib) to include adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news
Bio-Rad releases first CE-IVD digital PCR test for monitoring chronic myeloid leukemia response to therapy
(CG Life) Bio-Rad's QXDx BCR-ABL %IS Kit is the most sensitive diagnostic test available for monitoring deep molecular response of patients with chronic myeloid leukemia to tyrosine kinase inhibitor therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 4, 2017 Category: International Medicine & Public Health Source Type: news
FDA Expands Approval of Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
PRINCETON, N.J.--(BUSINESS WIRE) November 10, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel (dasatinib) tablets to include the treatment of children... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 10, 2017 Category: Drugs & Pharmacology Source Type: news
Novartis and The Max Foundation to provide cancer access programme in lower-income countries
Novartis has entered a new collaboration with The Max Foundation to support continued access to treatment free of charge for almost 34,000 patients suffering from chronic myeloid leukaemia (CML), gastrointestinal tumours (GIST) and other rare cancers … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 25, 2017 Category: Pharmaceuticals Source Type: news
Prostaglandin EI inhibits leukemia stem cells
(University of Iowa Health Care) Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2017 Category: Cancer & Oncology Source Type: news
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP), (Source: World Pharma News)
Source: World Pharma News - September 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Nigeria: Leukemia Patients Celebrate 10th World CML Day
[This Day] As patients of Chronic Myeloid Leukemia (CML) worldwide celebrate the 10th World CML Day today to raise awareness on a rare haematological disease that represents 15 to 20 per cent of all leukemia in adults and the needs of patients, a non-governmental organisation, Together Maxcare Foundation Nigeria, is pushing for more sensitivity to the plight of patients who have this rare type of leukemia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 22, 2017 Category: African Health Source Type: news
Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease
The tyrosine kinase inhibitor bosutinib, approved for chronic myeloid leukemia, reduced kidney growth rate in patients with autosomal dominant polycystic kidney disease (ADPKD) in a phase 2 study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 31, 2017 Category: Intensive Care Tags: Nephrology News Source Type: news
EMA accepts Pfizer ’s bosulif Type II Variation application for Ph+ CML
The European Medicines Agency (EMA) has approved for review a Type II Variation application for the use of Pfizer ’s bosulif (bosutinib) to treat patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news
CML Blast Phase Outcomes Remain Poor in TKI Era, Prognostic Factors Identified
Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
CML Patients Approach Normal Life Expectancy With Imatinib Treatment
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study. (Source: CancerNetwork)
Source: CancerNetwork - July 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
